Sangamo Gets Fast Track Designation For SB-525 Hemophilia A Gene Therapy – Nasdaq
|
Sangamo Gets Fast Track Designation For SB-525 Hemophilia A Gene Therapy
Nasdaq (RTTNews.com) – Sangamo Therapeutics Inc. ( SGMO ) said Tuesday that the U.S. Food and Drug Administration has granted Fast Track designation to SB-525, the Company’s clinical stage cDNA gene therapy candidate for hemophilia A, which is being … |
|
Athersys Poised For Lucrative Stem Cell Stroke Partnership This Year
Seeking Alpha Over the last few months, several SA followers have requested an update on stem cell biotech, Athersys Inc. (NASDAQ:ATHX). Realistically, there really hadn’t been any significant developments worthy of an update over the first part of 2017. On May 9th … |